Contrary to the therapeutic benefits of TLR7 agonists on the immune cells, two studies have shown that TLR7 can be highly expressed on primary tumor cells from NSCLC patients, and its stimulation on tumor cells promotes tumor progression and resistance to chemotherapy treatment in NSCLC patients who highly express TLR7. This evidence concerns the gene TLR7 and neoplasm.